All In Biotech

Drug Trial Radar · NCT01525602

Safety Study of PLX3397 and Paclitaxel in Patients With Advanced Solid Tumors

A Phase 1b Study to Assess the Safety of PLX3397 and Paclitaxel in Patients With Advanced Solid Tumors

Last checked: Nov 20, 2026Latest source record: Jul 16, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

74

Actual

Start

May 2012

Primary completion

Dec 2017

Study completion Feb 2018

Sponsor

Lead sponsor
Daiichi SankyoDaiichi Sankyo (DSNKY)
Sponsor type
Industry
Collaborators
Plexxikon
First posted
Feb 3, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This was a 3-part study designed to explore the safety and tolerability of escalating doses of PLX3397 with weekly paclitaxel to establish a recommended Phase 2 dose (RP2D), to confirm RP2D in participants with advanced non-resectable solid tumors, and to determine the efficacy of PLX3397 600 mg twice daily (BID) administered in combination with weekly paclitaxel in participants with advanced, metastatic or non-resectable, platinum-resistant or -refractory epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer.

Conditions

  • Solid Tumors

Interventions

  • PLX3397Drug

    PLX3397 tablets, 200mg

  • PaclitaxelDrug

    Paclitaxel IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Treatment-emergent Adverse Events (>10%) Classified by Preferred Term Following PLX3397 Administered in Combination With Paclitaxel (Parts 1 and 2) (Safety Population)Time frame: From post first dose up to 28 days after the last dose, up to 5 years 9 months
  2. Percentage of Participants With TEAEs (>10%) Classified by Preferred Term Following PLX3397 Administered in Combination With Paclitaxel (Part 3) (Safety Population)Time frame: From post first dose up to 28 days after the last dose, up to 5 years 9 months
  3. Best Overall Tumor Response Based on RECIST V1.1 Following PLX3397 Administered in Combination With Paclitaxel (Parts 1 and 2) (Efficacy Evaluable Population)Time frame: From post first dose up to 5 years 9 months post dose
  4. Best Overall Tumor Response Based on RECIST V1.1 Following PLX3397 Administered in Combination With Paclitaxel (Part 3) (Efficacy Evaluable Population)Time frame: From 26 days (CR and PR) and 54 days (SD) up to 5 years 9 months post dose

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • Univeristy of California, San Francisco

    San Francisco, California

  • University of Colorado, Anschutz Cancer Pavilion

    Aurora, Colorado

  • Sylvester Comprehensive Cancer Center/UMHC

    Miami, Florida

  • Mayo Clinic

    Rochester, Minnesota

  • University Hospitals of Cleveland

    Cleveland, Ohio

  • Ohio State University

    Columbus, Ohio

  • University of Utah, Huntsman Cancer Institute

    Salt Lake City, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.